TAS-116 is an orally bioavailable HSP90 inhibitor that showed potent anti-tumor activity in many in vitro and in vivo models. TAS-116 is a selective inhibitor of cytosolic HSP90? and ? that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1 [1]. Multiple clinical trials are on-going testing the synergistic anti-tumor effect of combined therapy strategy with TAS-116 for treatment of advanced solid tumors. TAS-116 has a potential to enhancing antitumor activity while minimizing adverse effects that are observed with other compounds of this class [2,3].

TAS-116 is an orally bioavailable HSP90 inhibitor that showed potent anti-tumor activity in many in vitro and in vivo models. TAS-116 is a selective inhibitor of cytosolic HSP90? and ? that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1 [1]. Multiple clinical trials are on-going testing the synergistic anti-tumor effect of combined therapy strategy with TAS-116 for treatment of advanced solid tumors. TAS-116 has a potential to enhancing antitumor activity while minimizing adverse effects that are observed with other compounds of this class [2,3].